AI assistant
GILEAD SCIENCES, INC. — Director's Dealing 2014
Jun 4, 2014
29828_dirs_2014-06-04_6bd82fe5-ac10-4cff-99a8-f75b4d4018f0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2014-06-02
Reporting Person: MARTIN JOHN C (Director, Chairman and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-06-02 | Common Stock | M | 140625 | $8.005 | Acquired | 4570012 | Direct |
| 2014-06-02 | Common Stock | S | 140625 | $81.3215 | Disposed | 4429387 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-06-02 | Non-Qualified Stock option (right to buy) | $8.005 | M | 140625 | Disposed | 2015-01-26 | Common Stock (140625) | Direct |
Footnotes
F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
F2: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
F3: Sale prices reported for the transactions reported here range from $80.76 to $81.72. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.